Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

Plain-language summary

This is a non-interventional, observational study that follows patients with transthyretin (ATTR) amyloidosis. It is enrolling patients aged 18 and older with a confirmed diagnosis of ATTR amyloidosis. It is being run as a study with no assigned phase and is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

AstraZeneca

Intervention

Treatment of transthyretin (ATTR) amyloidosis in observational study setting

Start date

6/25/2024

Estimated completion

12/29/2031

Countries

United States, Canada, China, Germany, Spain, United Kingdom

Related genes

Locations

• La Jolla, United States
• Los Angeles, United States
• San Francisco, United States
• San Francisco, United States
• New Haven, United States
• Washington D.C., United States
• Chicago, United States
• Indianapolis, United States
• Boston, United States
• Boston, United States
• Boston, United States
• Rochester, United States
• Kansas City, United States
• St Louis, United States
• New Brunswick, United States
• Manhasset, United States
• New York, United States
• New York, United States
• Durham, United States
• Portland, United States
• Danville, United States
• Philadelphia, United States
• Philadelphia, United States
• Greenville, United States
• Germantown, United States
• Nashville, United States
• Dallas, United States
• Richmond, United States
• Seattle, United States
• Milwaukee, United States
• Vancouver, Canada
• Vancouver, Canada
• Halifax, Canada
• London, Canada
• Toronto, Canada
• Rimouski, Canada
• Beijing, China
• Beijing, China
• Beijing, China
• Beijing, China

+34

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Patient willing and able to provide written informed consent to participate in the study
* Confirmed diagnosis of amyloid transthyretin (ATTR) amyloidosis
* Aged ≥18 years at the time of signing the informed consent
* Patient willing and able to participate in collection of electronic patient reported outcomes (PROs)

Exclusion Criteria:

* Concurrent participation in any interventional trial for ATTR amyloidosis
* Involvement in the planning and/or conduct of the current study
* Patients with evidence of primary or light chain amyloidosis (AL) or serum protein A amyloidosis (AA)
* Asymptomatic patients with ATTR amyloidosis and asymptomatic ATTR mutation carriers